To further validate the universal impact of TRKA‐GRB2 axis‐targeted molecular in enhancing CL expression and ameliorating PD, we employed Surface Plasmon Resonance (SPR) technology[58] to screen compounds that bind to GRB2 (Figure 8a). The gene discussed is GRB2; the disease is Parkinson disease.